Livedoid vasculopathy: What it is and how the patient should be evaluated and treated

Archives of Dermatology

Volumn 142, Issue 11, 2006, Pages 1481-1482

  Callen, Jeffrey P ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DANAZOL; DIPYRIDAMOLE; ENOXAPARIN; FOLIC ACID; HEPARIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; PENTOXIFYLLINE; STANOZOLOL; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

BLEEDING; DIFFERENTIAL DIAGNOSIS; EDITORIAL; HUMAN; HYPERBARIC OXYGEN; IMMUNOFLUORESCENCE MICROSCOPY; LIVEDO RETICULARIS; LIVEDOID VASCULOPATHY; MEDICAL PRACTICE; PRIORITY JOURNAL; SKIN DISEASE; SMOKING CESSATION;

DECISION TREES; DIAGNOSIS, DIFFERENTIAL; HUMANS; INFUSIONS, INTRAVENOUS; LEG ULCER; SKIN DISEASES, VASCULAR; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33751247618     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.11.1481     Document Type: Editorial

References (20)

1. Hairston BR, Davis MDP, Pittelkow MR, Ahmed I. Livedoid vasculopathy: further evidence for procoagulant pathogenesis. Arch Dermatol. 2006;142:1413-1418.
2. Deng A, Gocke CD, Hess J, Heyman M, Paltiel M, Gaspari A. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator. Arch Dermatol. 2006;142:1466-1469.
3. Jorizzo JL. Livedoid vasculopathy: what is it? Arch Dermatol. 1998;134:491-493.
4. Papi M, Didona B, De Pita O, et al. Livedo vasculopathy vs small vessel cutaneous vasculitis: cytokine and platelet P-selectin studies. Arch Dermatol. 1998;134:447-452.
5. Milstone LM, Braverman IM, Lucky P, Fleckman P. Classification and therapy of atrophie blanche. Arch Dermatol. 1983;119:963-969.
6. Milstone LM, Braverman IM. PURPLE (oops! atrophie blanche) revisited [letter]. Arch Dermatol. 1998;134:1634.
7. Klein KL, Pittelkow MR. Tissue plasminogen activator for the treatment of livedoid vasculitis. Mayo Clin Proc. 1992;67:923-933.
8. Wientraub MI. Thrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmire. Stroke. 2006;37:1917-1922.
9. Lewerenz V, Burchardt T, Buchau A, Ruzicka T, Megahed M. Livedoid vasculopathy with heterozygous factor V Leiden mutation and sticky platelet syndrome. Hautarzt. 2004;55:379-381.
10. Kern AB. Atrophie blanche: report of two patients treated with aspirin and dipyridamole. J Am Acad Dermatol. 1982;6:1048-1053.
11. Sauer GC. Pentoxifylline (Trental) therapy for the vasculitis of atrophie blanche. Arch Dermatol. 1986;122:380-381.
12. Sams WM. Livedo vasculitis: therapy with pentoxyfylline. Arch Dermatol. 1988;124:684-687.
13. Rampf J, Sunderkötter C, Scharffetter-Kochanek K, Weiss JM. Methylenetetrahydrofolate-reductase polymorphism associated homocysteinemia in a patient with livedo vasculopathy: therapy with vitamin substitution and low-molecular weight heparin. Br J Dermatol. http://www.blackwell-synergy.com/ doi/pdf/10.1111/j.1365-2133.2006.074.x.
14. Meiss F, Marsch WC, Fischer M. Livedoid vasculopathy: the role of hyperhomocysteinemia and its simple therapeutic consequences. Eur J Dermatol. 2006;16:159-162.
15. Falanga V, Kersner R, Eaglstein WH, Katz MH, Kerdel FA. Stanozolol in treatment of leg ulcers due to cryofibrinogenaemia. Lancet. 1991;338:347-348.
16. Hsiao GH, Chiu HC. Low-dose danazol in the treatment of livedoid vasculitis. Dermatology. 1997;194:251-255.
17. Browning CE, Callen JP. Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia. Arch Dermatol. 2006;142:75-78.
18. Heine KG, Davis GW. Idiopathic atrophie blanche: treatment with low-dose heparin. Arch Dermatol. 1986;122:855-856.
19. Juan WH, Chan YS, Lee JC, Yang LC, Hong HS, Yang CH. Livedoid vasculopathy: long-term follow-up results following hyperbaric oxygen therapy. Br J Dermatol. 2006;154:251-255.
20. Schanz S, Ulmer A, Fierbeck G. Intravenous immunoglobulin in livedo vasculitis: a new therapeutic option? J Am Acad Dermatol. 2003;49:555-556.